CGTN: Challenges, Goals and Proposals From Communique of China's Ruling Party Plenum
The 19th Central Committee of the Communist Party of China (CPC) concluded its fifth plenary session in Beijing on Thursday with the release of a communique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006395/en/
The 14th Five-Year Plan (FYP) (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035 are the key topics of the communique.
Here is a look at all the highlights from the communique of the meeting.
Read the original article: here.
Decisive success made in building a moderately prosperous society in all respects
This year is the final year of China's 13th FYP period (2016-2020) and the communique highlighted that the implementation of the 13th FYP has been smooth.
By adhering to the new development concept and unswervingly advancing reform and opening-up, great achievements have been made since the fourth plenary session, the communique said.
During the past year, China has deepened supply-side reform, enhanced macro-economic regulation and expanded domestic demand as the strategic foundation.
Economic growth has been better than expected, people's livelihood has been improved and social stability has been maintained.
During the 13th FYP period, which is coming to an end in 2020, China has made great progress with stable economic growth and better economic structure, the communique said, noting China's GDP is expected to surpass the 100 trillion yuan ($14.9 trillion) mark in 2020.
More than 55 million people in China have been lifted out of poverty in the past five years.
China has built the world's largest social security system in the 13th FYP period, the communique said, adding that the country's basic medical insurance has covered over 1.3 billion people, and basic old-age insurance has covered nearly 1 billion people.
Meanwhile, during the past five years, more than 60 million new jobs were created in China's urban areas, it said.
As for the fight against the COVID-19 pandemic, the whole country coordinated the prevention and control work with economic and social development and put people's safety and health first.
Major country diplomacy with Chinese characteristics was vigorously promoted, and major achievements were made in various undertakings of the Party and state.
The strength of the leadership of the CPC and the Chinese socialist system has been further demonstrated in the past five years, it added.
New challenges, opportunities and proposals ahead
With regards to the blueprint for the future, the communique stressed that the whole Party must take into account the overall strategic plan for the great rejuvenation of the Chinese nation with major changes in the world that have not occurred in a century.
A thorough understanding is necessary about the new characteristics and requirements brought about by the changes in the evolution of the principal contradiction facing Chinese society, it said.
Also, given that China is in the primary stage of socialism, more attention should be paid to the new contradictions and challenges brought by the complex international environment.
The communique underlined the importance of strengthening awareness of opportunities and risks and cultivating opportunities amid crisis.
Additionally, the CPC has raised a set of long-range objectives for China to achieve socialist modernization by 2035.
China's economic, technological and composite strength was also stressed, as well as development in new industrialization and the modernization of China's system and capacity for governance.
The communique also said effort was needed in boosting the well-rounded development of society, including social etiquette and civility and the advancement of eco-friendly ways of work and life.
China's opening-up, per capita GDP, the implementation of the Peaceful China initiative and well-rounded human development were also highlighted.
As for the goals to be reached during the 14 FYP period, the communique said that the overall leadership of the CPC must be upheld to realize the 14th FYP and efforts should be made to mobilize all positive factors and rally all the forces that can be rallied to form a strong synergy to promote development.
Several proposals to reach the goals
- Upholding the central role of innovation in its modernization drive and implementing the innovation-driven strategy.
- Building a modern industrial system and upgrading the economic structure. It will continue to support the real economy, improve manufacturing power and modernized industrial chain and supply chain, so as to improve high-quality growth and core competitiveness.
- Nurturing a strong domestic market and establishing a new development pattern. The country will smooth domestic circulation and let domestic and international circulations reinforce each other, spurring consumption in an all-round way and expanding investment.
- Deepening reform comprehensively in pursuit of a high-level socialist market economy.
- Prioritizing the development of agriculture and rural areas, and fully advancing rural vitalization.
- Advancing coordinated regional development and a new type of urbanization.
- Promoting cultural sector and improving its cultural soft power.
- Accelerating green and low-carbon development, continuously improving the environment as well as the quality and stability of ecosystems, and raising the efficiency of resource utilization.
- Pursuing high-level opening-up and exploring new prospects of win-win cooperation.
It will continue to widen the opening-up and leverage the advantages of its huge market to promote international cooperation and achieve win-win results.
- Improving people's standard of living, and actively implementing strategies to address ageing population.
- Strengthening national security capabilities and increasing the capacity to deal with traditional and non-traditional security challenges, so as to protect people's lives and security and maintain social stability.
- Maintaining the long-term prosperity and stability of the Hong Kong and Macao special administrative regions, and promoting the reunification of Chinese mainland and Taiwan as well as peaceful Cross-Strait development.
It aims to keep a stable external environment and promote the building of a new type of international relations and a community with a shared future for mankind.
A total of 198 members and 166 alternate members of the CPC Central Committee attended the meeting.
Also present were members of the Standing Committee of the CPC Central Commission for Discipline Inspection and senior officials of relevant sectors, as well as experts, scholars and several deputies of the 19th CPC National Congress who work at the grassroots level.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma4.12.2020 20:52:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation to pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37 percent, compared to Pd alone in patients with multiple myeloma (MM) after the first or subsequent relapse of disease.1 The APOLLO results, which will be presented on Sunday, December 6 at 9:00 p.m. CET during the American Society of Hematology (ASH) 2020 Annual Meeting and featured in the ASH press briefing (Abstract #112), add to the body of evidence supporting treatment with daratumumab SC-based regimens for patients with relapsed MM. These data were the basis for recent regulatory submissions in Europe and the United States (U.S.) seeking approval for daratumumab SC in combination with Pd for the treatment of patients with relapsed or refractory MM, with two or more prior lines of therapy, includi
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance